OBJECTIVES: To estimate the incidence of bleeding leading to death or hospital admission in out-patients treated with oral anticoagulants. DESIGN: Population-based historical cohort study 1 January 1992 to 31 September 1994. SETTING: The County of North Jutland, Denmark (488,000 inhabitants). SUBJECTS: Six hundred and eighty-two consecutive patients commencing oral anticoagulant therapy. MAIN OUTCOME MEASURES: Fatal bleeding or bleeding demanding hospital admission. RESULTS: In 756 treatment-years of follow-up, there were 45 major haemorrhagic events (6.0 per 100 treatment-years) in 42 patients, of which seven (0.9 per 100 treatment-years) were fatal. The risk of a first major haemorrhagic episode was highest during the first 90 days of treatment compared with duration above one year (incidence rate ratio, IRR, 1.9; 95% CI, 0.8-4.1). The rate was highest above the age of 60 years, 6.8 per 100 treatment-years, compared with 2.9 per 100 treatment-years below 60 years (IRR 2.3; 95% CI, 1.0-5.6). The rate for a bleeding event was slightly higher in females than in males (IRR 1.3; 95% CI, 0.7-2.3), but did not vary according to type of anticoagulant drug. CONCLUSIONS: The reported rates of major bleeding in this routine community setting implied a higher bleeding risk than was found in randomized trials or when patients are monitored in specialist anticoagulation clinics.
OBJECTIVES: To estimate the incidence of bleeding leading to death or hospital admission in out-patients treated with oral anticoagulants. DESIGN: Population-based historical cohort study 1 January 1992 to 31 September 1994. SETTING: The County of North Jutland, Denmark (488,000 inhabitants). SUBJECTS: Six hundred and eighty-two consecutive patients commencing oral anticoagulant therapy. MAIN OUTCOME MEASURES: Fatal bleeding or bleeding demanding hospital admission. RESULTS: In 756 treatment-years of follow-up, there were 45 major haemorrhagic events (6.0 per 100 treatment-years) in 42 patients, of which seven (0.9 per 100 treatment-years) were fatal. The risk of a first major haemorrhagic episode was highest during the first 90 days of treatment compared with duration above one year (incidence rate ratio, IRR, 1.9; 95% CI, 0.8-4.1). The rate was highest above the age of 60 years, 6.8 per 100 treatment-years, compared with 2.9 per 100 treatment-years below 60 years (IRR 2.3; 95% CI, 1.0-5.6). The rate for a bleeding event was slightly higher in females than in males (IRR 1.3; 95% CI, 0.7-2.3), but did not vary according to type of anticoagulant drug. CONCLUSIONS: The reported rates of major bleeding in this routine community setting implied a higher bleeding risk than was found in randomized trials or when patients are monitored in specialist anticoagulation clinics.
Authors: Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss Journal: Blood Date: 2014-05-23 Impact factor: 22.113
Authors: A Cantalapiedra; O Gutierrez; J I Tortosa; M Yañez; M Dueñas; E Fernandez Fontecha; M J Peñarrubia; L J García-Frade Journal: J Thromb Thrombolysis Date: 2006-10 Impact factor: 2.300
Authors: Anton Pottegård; Peter M Meegaard; Line H V Holck; Rene dePont Christensen; Hanne Madsen; Jesper Hallas Journal: Eur J Clin Pharmacol Date: 2012-07-31 Impact factor: 2.953
Authors: Frederick A Spencer; Joel M Gore; George Reed; Darleen Lessard; Luigi Pacifico; Cathy Emery; Mark A Crowther; Robert J Goldberg Journal: Thromb Haemost Date: 2009-05 Impact factor: 5.249
Authors: Claudia Stöllberger; Josef Finsterer; Thomas Länger; Barbara Schneider; Cornelius Wehinger; Pierre Hopmeier; Jörg Slany Journal: J Thromb Thrombolysis Date: 2002-08 Impact factor: 2.300